A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanoma
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 23 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 23 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.